NatImmune and Enzon enter into a License Agreement

NatImmune A/S and US-based Enzon Pharmaceuticals, Inc. have entered into a license agreement for NatImmune's lead development product, recombinant human Mannan-Binding Lectin, rhMBL, a protein therapeutic being developed for the prevention of severe infections in MBL-deficient individuals undergoing chemotherapy. Under the agreement, Enzon receives exclusive worldwide rights, excluding the Nordic countries, and is responsible for the development, manufacture, and marketing of rhMBL. NatImmune will receive an upfront payment of $10 million and is eligible to receive additional payments upon the successful completion of certain clinical development, regulatory, and sales-based milestones. NatImmune is also eligible to receive royalties from any future product sales of rhMBL by Enzon and retains certain rights to develop a non-systemic formulation for topical administration of MBL.

Numerous studies have found a strong correlation between MBL-deficiency and an increased susceptibility to infections in patients with a suppressed immune system, such as cancer patients undergoing treatment with chemotherapy. In addition, a number of publications have also highlighted the potentially important future role of MBL replacement therapy in preventing serious infections in other critical care areas associated with immunodeficiency.

Mannan-Binding Lectin is a naturally occurring human plasma protein that plays a key role in the immune system's first-line defense against infections. MBL binds to a wide range of invading organisms, including bacteria, fungi, viruses, and parasites and activates the lectin pathway of the complement system, an important defense mechanism of the immune system.

NatImmune A/S is a biotech company focused on the development of therapeutic proteins. Based in Symbion Science Park, the company was founded in 2000 and has 22 employees. NatImmune's lead product, Mannan Binding Lectin (MBL), has completed Phase 1 clinical trials and is being developed under a global licensing agreement with the U.S. biopharmaceutical company, Enzon Pharmaceuticals, Inc. NatImmune has retained certain rights to develop a nonsystemic formulation for the topical administration of MBL. In addition, the company's pipeline also includes antibodies for the treatment of colorectal cancer, COU-I, and cardiovascular diseases, MASP-2.

For further information please contact:

Martin Bonde,

CEO

Tel: +45 70 22 35 60

Email: bhs@natimmune.dk

Or visit: www.natimmune.com